Cellectis (United States)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Immunology and Microbiology 21.1×
• Biochemistry, Genetics and Molecular Biology 4.4×
• Medicine 2.6×
• Engineering 0.4×

By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Tumor Regression, CAR T Cells, Chimeric Antigen Receptor, Genome Engineering, RNA-Guided and Biopharmaceutical Production.

By volume in 2022–2025: CAR-T cell therapy research, Immunotherapy and Immune Responses, CRISPR and Genetic Engineering and Biosimilars and Bioanalytical Methods.

1. 1 CAR-T cell therapy research Oncology 4 works
2. 2 Immunotherapy and Immune Responses Immunology 1 works
3. 3 CRISPR and Genetic Engineering Molecular Biology 0 works
4. 4 Biosimilars and Bioanalytical Methods Immunology 0 works
5. 5 Virus-based gene therapy research Genetics 0 works
6. 6 T-cell and B-cell Immunology Immunology 0 works
7. 7 Nanowire Synthesis and Applications Biomedical Engineering 0 works
8. 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
9. 9 RNA Interference and Gene Delivery Molecular Biology 0 works
10. 10 Immune Cell Function and Interaction Immunology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 13% lower than in 2013–2017.

• Wilson Wolf Manufacturing (United States)
• APi Group (United States)